Abstract
Both fluticasone and formoterol are substances commonly used in clinical setting with sufficiently known efficacy and undesirable effects profile. Formoterol counts among long-acting β 2 -agonists, and is also characterized by rapid onset of action.
Fluticasone propionate belongs to long corticosteroids with pronounced anti-inflammatory and vasoconstriction activities. The fixed-dose combination of fluticasone with formoterol is supported by multiple evidence of its efficacy, compared to not only both active substances when used concurrently but separately, but also in comparison to both substances when used individually.